Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00537563
Other study ID # HMR3647A_4017
Secondary ID
Status Completed
Phase Phase 3
First received September 28, 2007
Last updated February 15, 2012
Start date December 2002
Est. completion date September 2003

Study information

Verified date February 2012
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure visit, and to assess the safety of telithromycin given once daily for 5 days vs moxifloxacin given once daily for 10 days in the treatment of subjects with AMS.


Recruitment information / eligibility

Status Completed
Enrollment 351
Est. completion date September 2003
Est. primary completion date September 2003
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult subjects, aged 18 years or older, AMS diagnosed (clinically and radiologically) who were willing to undergo rhinoscopic aspiration or deep nasal swab at the baseline/pre-therapy visit. Female subjects of childbearing potential were required to have a negative pregnancy test before undergoing any study procedure and to use an accepted contraceptive method during the study.

Exclusion Criteria:

- Women who were breast-feeding or pregnant, as demonstrated by serum or urine pregnancy tests carried out before exposure to study medication or the start of any study procedure that could pose a risk to the fetus;

- Subjects with a history of recurrent sinusitis (defined as more than 3 episodes of sinusitis that required antibiotic therapy in the preceding 12 months);

- Subjects with a history of chronic sinusitis (defined as symptoms lasting greater than 28 days);

- Subjects with sphenoidal sinusitis involvement that required treatment other than oral antibiotics;

- Subjects with nosocomial-acquired sinusitis within 2 weeks (eg, hospitalization or nonambulatory, institutional confinement, including nursing homes);

- Subjects with any concomitant medication [including functionally significant, major obstructive anatomical lesions likely to impair resolution of infection (eg, nasal polyps extending past the middle turbinate, tumor, or severe septal deviation)], such as: asthma, cystic fibrosis, immotile cilia syndrome, prior nasopharyngeal or sinus surgery, sinus polyps, clinically relevant cardiovascular (eg, congestive heart failure), neurologic, endocrine, or other major systemic disease that could have made implementation of the protocol or interpretation of the study results difficult;

- Subjects with a need for immediate surgery for maxillary sinusitis;

- Subjects who used nasal, nasogastric, or nasotracheal catheters;

- Subjects with previous sinus surgery within the past 6 months or sinus lavage within the past 7 days;

- Subject who were long-term (> than or = to 4 weeks) users of nasal decongestants like oxymetazoline 0.05%;

- Subjects with suspected nonbacterial infections;

- Subjects with a concomitant odontological infection that would require antibiotic therapy or surgery;

- Subjects with unknown or suspected hypersensitivity to, or a known or suspected serious adverse reaction to either study medication, any fluoroquinolone, or any macrolide antibiotic;

- Subjects who would likely have required on-study treatment with drugs known to have contraindicated drug interactions with either study medication and/or macrolides or fluoroquinolones in general, including, but not limited to: ergot alkaloid derivatives, cholinesterase inhibitors (eg, tacrine, donepezil, physostigmine) ketamine, carbamazepine, St John's Wort, Class IA (eg, quinidine, procainamide), or Class III antiarrhythmic agents (eg, amiodarone, sotalol);

- Subjects who required anticoagulant therapy (eg, warfarin);

- Subjects who received treatment with other systemic antibiotics (oral or parenteral) within 14 days prior to study enrollment;

- Subject who received moxifloxacin or another fluoroquinolone antibiotic for this infectious episode;

- Likelihood of required treatment during the study period with drugs not permitted by the protocol;

- Treatment with any investigational product in the last 1 month prior to study entry;

- Subjects with a progressively fatal disease; life expectancy <less than or = to 3 months;

- Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult;

- History of drug or alcohol abuse;

- Impaired hepatic function [as shown by previous clinical laboratory values of AST (SGOT) and/or ALT (SGPT) > than or = to 3 times the upper limit of reference range, total bilirubin > than 2 times the upper limit of reference range (except for Gilbert's disease), encephalopathy, etc];

- Impaired renal function [as shown by previous clinical laboratory values of creatinine clearance < than or = to 30 mL/min (< than or = to 0.50 mL/sec), serum creatinine > than or = to 2.0 mg/dl (> than or = to 176 micromol/L), etc]. Creatinine clearance may have been estimated by formula or by nomogram;

- Immunocompromised subjects, such as subjects with HIV infection and who had either an AIDS-defining condition (eg, Kaposi's sarcoma and Pneumocystis carinii pneumonia), or a CD4 + T-lymphocyte count of < 200/mm3). A complete list is provided in Appendix 3 of the clinical study protocol (see @@Appendix A.1.1).

- subjects with neutropenia (<1500 neutrophils/mm3) not attributable to the acute infectious disease

- subjects with metastatic or hematological malignancy

- splenectomised subjects with known hyposplenia or asplenia

- subjects with known IgG deficiency

- Subject with known long QT syndrome or familiar history of long QT syndrome (if no previous ECG has invalidated this risk factor), or personal history of coronary disease, ventricular arrhythmia, bradycardia < 50 beats/min, or known uncorrected hypokalemia or hypomagnesemia, or who were treated with concomitant medication known to prolong QT interval (eg, cisapride, pimozide, astemizaole, terfenadine, or potent CYP3A4 inhibitors, such as: protease inhibitors, ketoconazole);

- Mental condition that rendered the subject unable to understand the nature, scope, and possible consequences of the study;

- Subjects diagnosed with myasthenia gravis (ie, Protocol Amendment No. 1);

- Subjects unlikely to comply with the protocol (eg, uncooperative attitude, inability to return for follow-up visit, and unlikely to complete the study);

- Subjects without a permanent residential address or home telephone number;

- Any waiver of these inclusion/exclusion criteria was to be approved by the investigator and Aventis on a case-by-case basis, prior to study enrollment. This was to be documented by both the investigator and Aventis; or

- No subject was allowed to enroll in this study more than once.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Telithromycin


Locations

Country Name City State
United States Sanofi-Aventis Bridgewater New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To demonstrate equivalence in clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure (TOC) visit. Days 17 to 24
Secondary Assess the safety of telithromycin given once daily for 5 days vs moxifloxacin given once daily for 10 days in the treatment of subjects with AMS.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04903418 - Assessment of Relationship Between Maxillary Sinus Floor and Maxillary Posterior Teeth Root Tips Position
Completed NCT00683371 - Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis N/A
Completed NCT00236652 - A Study Evaluating the Safety and Efficacy of Treating Sinus Infection With Levofloxacin 750 mg for 5 Days. Phase 3
Recruiting NCT06130176 - Single-step Functional Sinus Endoscopy and Transoral Surgery N/A
Recruiting NCT04241016 - Endoscopic Sinus Surgery in Recurrent Acute Rhinosinusitis N/A
Not yet recruiting NCT03083392 - Endosseous Oroantral Port for Minimal Intervention in Treating Chronic Sinusitis N/A
Completed NCT00668304 - Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox Phase 4
Recruiting NCT04645511 - Balloon Sinuplasty Efficiency in Maxillary Rhinosinusitis. N/A
Not yet recruiting NCT02931604 - Study Designed to Clinically Evaluate Sinus Wash Device Prototypes N/A
Completed NCT00643409 - A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults Phase 3
Terminated NCT00245440 - Study to Measure the Impact of Antibiotics on Bacterial Flora in Adults With Acute Sinusitis Phase 4
Completed NCT00249210 - A Study of the Safety and Effectiveness of Levofloxacin Compared With Amoxicillin/Clavulanate Potassium in the Treatment of Adults With Rapid Onset of Severe Inflammation/Infection of the Sinuses Phase 3
Completed NCT01032174 - Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis N/A